The NM_000023.4: c.265C>T variant in SGCA is a missense variant predicted to cause substitution of leucine by phenylalanine at amino acid 89, p.(Leu89Phe). This variant has been detected in at least one individual with limb girdle muscular dystrophy, where it was reported in unconfirmed phase with a likely pathogenic variant (c.613C>T p.(Pro205Ser), 0.25 pts, GRASP-LGMD Consortium, Newcastle University internal data communication) (PM3_Supporting not met). This patient displayed progressive limb girdle muscle weakness and significantly reduced alpha-sarcoglycan protein expression, which is highly specific for SGCA-related LGMD (PP4_Strong). The upper bound of the 95% confidence interval of the Grpmax variant allele frequency in gnomAD v4.1.1 is 0.000014 (10/1179660 European (non-Finnish) alleles), which is lower than the LGMD VCEP threshold (<0.00009) for PM2_Supporting, and therefore meets this criterion. An in vitro assay in a heterologous cell system has demonstrated that this variant disrupts membrane localization of the sarcoglycan complex (PS3_Moderate, Washington University internal data). The computational predictor REVEL also gives a score of 0.836, which is above the threshold of 0.7, evidence that correlates with impact to SGCA function (PP3). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive limb-girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (specification guidelines for SGCA version v2.0.0; 04/29/2026): PP4_Strong, PS3_Moderate, PM2_Supporting, PP3.